MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

New compound inhibits pancreatic cancer

EQon Pharmaceuticals (Indiana University)

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortalities of all malignancies, with aggressive biology, resistance to therapeutic agents, and a mere 5-year survival of 8-9%. However, the current standard first-line treatment approach of Gemcitabine/Nab-Paclitaxel gives a median overall survival of only ~8.5 months with concerning toxic side effects like leukopenia and febrile neutropenia. These poor outcomes urgently demand for novel treatment options for pancreatic cancer patients.

Researchers at Indiana University have identified a new class of potential anticancer drugs for treating pancreatic cancers. These potential drugs have a new mode of action, have shown strong efficacy and no overt toxicity in animal models, and are being developed further by EQon Pharmaceuticals, an Indiana-based small business founded by inventor Dr. Tao Lu (Indiana University).

The new class of compounds are covered by US Patent No. 11,034,689 and pending global applications. EQon is actively looking for industry partners and investors to advance this cutting-edge technology to the clinic.

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights

An error has occured.